JP7403426B2 - Pharmaceutical units and vehicles - Google Patents

Description

TECHNICAL FIELD The present invention relates to a drug unit configured to be attachable to a vehicle and a vehicle.

This type of device is a device that releases the odor from an air freshener that has traditionally been placed inside a vehicle's instrument panel to the outside of the instrument panel through an opening formed at the side edge of the instrument panel. is known (for example, see Patent Document 1). The device described in Patent Document 1 is configured such that the opening is closed when the front door of the vehicle is closed.

Publication No. 7-26182

However, in the device described in Patent Document 1, the aromatic agent is disposed inside the instrument panel, so the structure of the device becomes large-scale, resulting in a significant increase in cost. Moreover, the place where the air freshener can be installed is also limited.

One aspect of the present invention is a drug unit provided between a pair of opposing surfaces on a vehicle main body side and a door side that face each other when a door provided in a vehicle main body is closed, the drug unit being provided between a pair of opposing surfaces on a vehicle main body side and a door side, The entire body has a generally flat shape so as to be disposed in the gap between the two, and includes a case containing a volatile drug. The pair of opposing surfaces are a first opposing surface on either the vehicle body side or the door side and a second opposing surface on the other, and the case has a mounting surface attached to the first opposing surface , a drug and a case. a passage communicating with an external space; and a shutter portion configured to block the passage by a pressing force from the second opposing surface and open the passage when the pressing force from the second opposing surface is removed. , has.

A vehicle according to another aspect of the present invention includes the above-described drug unit, a vehicle body in which an opening is formed, and a door provided in the vehicle body to open and close the opening. The vehicle body or door has an attachment surface to which the drug unit is attached.

According to the present invention, a highly durable drug unit can be constructed at low cost. Furthermore, since there is a high degree of freedom in the mounting location of the drug unit, volatile drug components can be efficiently diffused in the required locations.

1 is a side view of a vehicle to which a drug unit according to an embodiment of the present invention is applied. 1 is a diagram showing an example of how a drug unit according to an embodiment of the present invention is attached to a vehicle; FIG. FIG. 2 is a perspective view showing the configuration of main parts of the vehicle in FIG. 1 when the rear door is closed. FIG. 1 is a perspective view showing an assembled state of a drug unit according to an embodiment of the present invention. FIG. 1 is an exploded perspective view of a drug unit according to an embodiment of the present invention. FIG. 6 is a perspective view showing a state in which the drug unit according to the embodiment of the present invention is further disassembled from the state in FIG. 5; 6 is a sectional view taken along the line VII-VII in FIG. 5, and corresponds to the open state of the rear door in FIG. 1. FIG. 6 is a cross-sectional view taken along line VII-VII in FIG. 5, and corresponds to the closed state of the rear door in FIG. 1. FIG. 6 is a sectional view taken along the line VIII-VIII in FIG. 5, and corresponds to the open state of the rear door in FIG. 1. FIG. FIG. 6 is a sectional view taken along line VIII-VIII in FIG. 5, and corresponds to the closed state of the rear door in FIG. 1; FIG. 2 is a cross-sectional view showing an example of the operation of the medicine unit according to the embodiment of the present invention, and corresponds to the open state of the rear door in FIG. 1. FIG. FIG. 2 is a cross-sectional view showing an example of the operation of the medicine unit according to the embodiment of the present invention, and corresponds to the closed state of the rear door in FIG. 1. FIG. The figure which shows the other example of attachment to the vehicle of the medicine unit based on embodiment of this invention. FIG. 7 is a diagram showing still another example of how the drug unit according to the embodiment of the present invention is attached to a vehicle. FIG. 7 is a diagram showing still another example of how the drug unit according to the embodiment of the present invention is attached to a vehicle.

An embodiment of the present invention will be described below with reference to FIGS. 1 to 12. The drug unit according to the embodiment of the present invention can be applied to various vehicles that have an opening, that is, a door, that is opened and closed when passengers get on and off the vehicle. FIG. 1 is a side view of a vehicle 1 to which a drug unit according to the present embodiment is applied. Note that FIG. 1 shows the front-rear direction, left-right direction, and up-down direction of the vehicle 1.

As shown in FIG. 1, a vehicle 1 has a pair of left and right front doors 3 and a rear door 4 (only the right side is shown) that are supported by a body frame 2 so as to be openable and closable. It is possible to get on and off the vehicle 1 via 3 and 4. The rear door 4 is a sliding door that slides rearward along the side of the vehicle 1. The vehicle body frame 2 constitutes a skeleton member that forms the skeleton of the vehicle 1. A center pillar 5, which is a part of the vehicle body frame 2, is provided between the front door 3 and the rear door 4. The drug unit according to this embodiment is attached to a frame member (such as the center pillar 5) around the opening of the vehicle 1 or to the peripheral edge of the doors 3 and 4 that open and close the opening.

FIG. 2 is a diagram showing an example of how the drug unit 10 according to the present embodiment is attached to the vehicle 1, and is a diagram of the frame of the right rear door 4 viewed from the inside of the vehicle. As shown in FIG. 2, the rear door 4 has a front end surface 4a extending in the vertical direction at its front end. The drug unit 10 is mounted at the vertical center of the front end surface 4a or at a flat position above the center.

FIG. 3 is a perspective view showing the main structure of the vehicle 1 when the rear door 4 is closed. As shown in FIG. 3, in the closed state of the rear door 4, a gap CL having a predetermined length (for example, about 10 mm) in the longitudinal direction is provided between the front end surface 4a of the rear door 4 and the rear end surface 5a of the center pillar 5. The drug unit 10 is interposed in this gap CL. Note that the gap CL is provided in advance regardless of whether or not the drug unit 10 is attached. A cushioning material 15 is attached to the rear end surface 5a of the center pillar 5 in correspondence with the position of the drug unit 10 attached to the front end surface 4a of the rear door 4. The front surface of the drug unit 10 is pressed through the cushion material 15 when the rear door 4 is closed.

The drug unit 10 is constructed by combining a plurality of parts. FIG. 4 is a perspective view showing the assembled state of the medicine unit 10, and FIG. 5 is an exploded perspective view of the medicine unit 10. In addition, below, the front-back direction, the left-right direction, and the up-down direction will be defined as shown in FIGS. 3 and 4 based on the mounting state of FIG. 2, and the configuration of each part will be explained according to these definitions. As shown in FIGS. 4 and 5, the drug unit 10 includes a base section 20 disposed on the rear side, a cover section 30 disposed on the front side, and a sheet disposed between the base section 20 and the cover section 30. material 11.

As shown in FIG. 4, the drug unit 10 has a substantially rectangular shape as a whole in the assembled state, and the length (thickness) in the front-rear direction includes a front end surface 4a of the rear door 4 and a center pillar 5 facing the front end surface 4a. The gap CL is formed to be thinner (for example, about 2 to 3 mm thinner) than the gap CL between the rear end surface 5a and the rear end surface 5a. For example, the medicine unit 10 has a thickness of about 5 mm to 10 mm, is shorter in the front-rear direction than in the left-right direction and the up-down direction, and has a generally flat shape as a whole. The base portion 20 and the cover portion 30 are each constructed by combining a plurality of parts. Each part of the drug unit 10 is configured vertically and horizontally symmetrically, respectively.

FIG. 6 is an exploded perspective view of the medicine unit 10 with the base part 20 and cover part 30 disassembled. As shown in FIG. 6, the base portion 20 includes an adhesive tape 21, a holder 22, and a sealing material 23. The holder 22 has a substantially rectangular plate portion 221 that is elongated in the vertical direction, and vertical and horizontal partition walls 222 that have a substantially rectangular frame shape and protrude from the front surface of the plate portion 221, and is entirely made of resin. Consisted of. Furthermore, the holder 22 has a pair of left and right engaging claws 223 that protrude from the front surface of the plate portion 221 above the upper partition wall 222 and below the lower partition wall 222, respectively. A pair of upper and lower protrusions 225 are provided on the left and right outer side surfaces of the left and right partition walls 222 .

The adhesive tape 21 is, for example, a double-sided tape having adhesive surfaces (front adhesive surface 211 and rear adhesive surface 212) on its front and rear surfaces, respectively, and the front adhesive surface 211 of the adhesive tape 21 is adhered to the rear surface of the holder 22. Ru. Note that the rear adhesive surface 212 is adhered to the front end surface 4a of the rear door 4 (FIG. 2), thereby fixing the base portion 20 to the rear door 4. The sealing material 23 is made of an elastic rubber material or the like. The holder 22 is provided with a substantially rectangular recess 224 inside the partition wall 222 , and the sealing material 23 is attached to the front end surface of the partition wall 222 .

The sheet material 11 is made of, for example, a non-woven fabric or woven fabric such as a mat or felt, or a resin such as a sponge. That is, the sheet material 11 is made of a member that can be impregnated with a drug. The sheet material 11 is impregnated in advance with an aromatic agent as a volatile chemical. Note that instead of the aromatic agent, a repellent containing an odor component disliked by pests and the like may be used as the medicine. It is also possible to use an odorless type of agent that does not emit an odor. The sheet material 11 impregnated with the drug is housed in the recess 224 of the holder 22 with its periphery sealed by the sealing material 23 . In addition, below, the example which uses an aromatic agent as a medicine is demonstrated.

The cover section 30 includes an inner cover 31, a sealing material 32, a spring 33, and a surface cover 34. The inner cover 31 has a substantially rectangular plate portion 311 that corresponds to the holder 22, and a pair of left and right engaging claws 312 that protrude toward the front above and below the plate portion 311, and is entirely made of resin. Composed of wood. Flange portions 313 are provided above and below the plate portion 311, and are connected to the upper and lower ends of the plate portion 311 and extend substantially parallel to the plate portion 311 behind the plate portion 311. It protrudes from both left and right ends of the front surface of the portion 313. Concave spring receivers 313a are provided at the center portions of the upper and lower flange portions 313 in the left-right direction, respectively.

A pair of left and right side walls 314 are provided at both left and right end portions of the plate portion 311 to protrude rearward. The side wall 314 is provided with a pair of upper and lower engagement holes 314a corresponding to the projections 225 of the holder 22. When the drug unit 10 is assembled, the partition wall 222 of the holder is accommodated inside the side wall 314, and the protrusion 225 is engaged with the engagement hole 314a. Thereby, the inner cover 31 is assembled to the holder 22. At this time, the engaging claws 223 of the holder 22 are inserted inside the left and right engaging claws 312 of the internal cover 31. The inner cover 31 can be removed from the holder 22 by pushing the side walls 314 outward in the left-right direction.

A recess 315 that is substantially rectangular in front view is provided on the front surface of the plate portion 311 over almost the entire area thereof. The bottom surface of the recess 315 is provided with a plurality of first protrusions 316 and second protrusions 317 that protrude forward in the vertical direction. FIG. 7A is a diagram showing the main part configuration of the cover part 30 in an assembled state, and is a sectional view taken along the line VII-VII in FIG. 5. FIG.

As shown in FIGS. 6 and 7A, the plurality of first convex portions 316 are each formed to be elongated in the left-right direction, and are arranged at equal intervals in the vertical direction, and their tip portions are located in front of the surface of the plate portion 311. stand out. The upper and lower corners of the tip of the first convex portion 316 are tapered (tapered portion 316a in FIG. 7A). The plurality of second convex portions 317 are each formed to be elongated in the left-right direction, and are arranged at equal intervals in the vertical direction and alternately with the first convex portions 316 in the vertical direction. The front surface of the second convex portion 317 is located on the same plane or substantially on the same plane as the front surface of the plate portion 311 outside the concave portion 315, and the second convex portion 317 has a smaller protrusion amount than the first convex portion 316. A slit hole 318 is formed in the center of each of the plurality of second convex portions 317 to be elongated in the left-right direction. The plurality of slit holes 318 are each formed to be elongated in the left-right direction. The front upper and lower edges of the slit hole 318 are tapered (tapered portion 318a in FIG. 7A).

The sealing material 32 has a generally rectangular plate shape with a constant thickness, corresponding to the recess 315 of the inner cover 31, and is made of a resilient rubber material or the like. The sealing material 32 is accommodated in a recess 315 on the front surface of the plate portion 311. The thickness (length in the front-rear direction) of the sealing material 32 is formed to be thicker than the depth of the recess 315 . A plurality of two types of slit holes (a first slit hole 321 and a second slit hole 322) which are elongated in the left and right direction are opened in the sealing material 32 alternately in the vertical direction. The first slit hole 321 has a shorter vertical opening length than the second slit hole 322.

The first convex portion 316 of the plate portion 311 is fitted into the first slit hole 321, thereby positioning the sealing material 32 with respect to the inner cover 31. The thickness of the sealing material 32 is thinner than the protrusion length of the first protrusion 316, and the front end of the first protrusion 316 protrudes further forward than the sealing material 32. The second convex portion 317 of the plate portion 311 is fitted into the second slit hole 322 .

The pair of upper and lower springs 33 is composed of, for example, a coil spring (compression coil spring). These springs 33 are respectively arranged in concave, more specifically cylindrical concave spring receivers 313a provided at the upper and lower ends of the inner cover 31.

The surface cover 34 has a substantially rectangular plate portion 341 extending in the vertical and horizontal directions, and a pair of substantially rectangular left and right plate portions 342 extending rearward from the left and right side edges of the plate portion 341. However, the entire structure is made of resin material. The plate portion 341 is provided with a plurality of vertically protruding portions 343 that protrude rearward, corresponding to the slit holes 318 of the inner cover 31 . The upper and lower corners of the tip of the convex portion 343 are formed into a tapered shape corresponding to the tapered portion 318a of the slit hole 318 (tapered portion 343a in FIG. 7A).

Further, in the plate portion 341, slit holes 344, which are elongated in the left-right direction and correspond to the plurality of first convex portions 316 of the inner cover 31, are opened at a plurality of locations in the vertical direction. The upper and lower edges on the rear side of the slit hole 344 are formed in a tapered shape corresponding to the tapered portion 316a of the first convex portion 316 (tapered portion 344a in FIG. 7A). In the left and right plate portions 342, vertically elongated slit holes 342a are opened at a plurality of locations at equal intervals in the vertical direction. More specifically, the slit hole 342a is formed over a region between a pair of upper and lower slit holes 344 arranged vertically. In other words, the upper end of the slit hole 342a and the lower end of the upper slit hole 344 of the vertically arranged slit holes 344 are located at approximately the same position in the vertical direction, and the lower end of the slit hole 342a The upper end of the lower slit hole 344 among the lined slit holes 344 is located at substantially the same position in the vertical direction.

Guides 345 are provided at the upper and lower ends of the plate portion 341, respectively, to protrude rearward. Both left and right end portions of the guide 345 are connected to the plate portion 342, and the entire rear surface of the front cover 34 is formed into a substantially rectangular concave shape. On the inside of the guide 345 in the vertical direction, a substantially cylindrical pin 346 is provided to protrude in correspondence with the spring receiver 313a. The pin 346 is inserted into the spring (coil spring) 33 and restricts the position of the spring 33.

As shown in FIG. 6, the plate portion 341 has a pair of left and right holes above the top slit hole 344 and below the bottom slit hole 344 corresponding to the engaging claws 312 of the inner cover 31. Through holes 347 are respectively opened. 8A is a cross-sectional view taken along line VIII-VIII in FIG. 5. FIG. As shown in FIG. 8A, the engagement claws 312 protrude from both left and right ends of the flange portion 313 of the internal cover 31, and at the distal ends of the engagement claws 312, claws 312a are provided in a stepped manner in the left-right direction. The claw portion 312a engages with a step portion 342b that is provided at the rear end of the plate portion 342 and protrudes inward in the left-right direction. The stepped portion 342b functions as a stopper, and the engagement between the claw portion 312a and the stepped portion 342b limits forward movement of the front cover 34 due to the biasing force of the spring 33.

The through hole 347 of the front cover 34 is provided corresponding to the claw portion 312a so that the claw portion 312a can be inserted therethrough when the front cover 34 is pushed backward. That is, although the front cover 34 is pushed through the cushion material 15 when the rear door 4 is closed (FIG. 3), the through holes 347 are provided so that the claw portions 312a do not interfere with the front cover 34 at that time.

FIG. 7A corresponds to a state in which no rearward pressing force is applied to the front cover 34 via the cushion material 15, that is, a state in which the rear door 4 is open. In this state, a substantially box-shaped space SP0 is formed between the plate part 311 of the inner cover 31 and the plate part 341 of the front cover 34, and the rear space SP1 of the plate part 311 and the plate part 341 are connected via the space SP0. It communicates with the front space SP2. That is, the cover part 30 has a plurality of passages PA (some of which are indicated by arrows in FIG. 7A) that pass through the inside of the cover part 30 by the slit hole 318 of the plate part 311 and the slit holes 344, 342a of the plate part 341. is formed, and the rear space SP1 of the plate part 311 and the front space SP2 of the plate part 341 communicate with each other via the passage PA. The slit hole 318 of the inner cover 31 and the slit hole 344 of the front cover 34 are provided with their positions shifted from each other in the vertical direction. For this reason, the passage PA is not formed linearly in the front-rear direction but curved.

7B and 8B are cross-sectional views showing an example of the operation of the cover portion 30 when the rear door 4 is closed, respectively, and correspond to FIGS. 7A and 8A. Note that in FIGS. 7B and 8B, illustration of the spring 33 is omitted for convenience.

As shown in FIG. 7B, when the rear door 4 is closed, the front cover 34 is pushed rearward, and the rear surface of the plate portion 341 of the front cover 34 comes into contact with the front surface of the sealing material 32. At this time, the convex portion 343 of the front cover 34 fits into the slit hole 318 of the inner cover 31 with the tapered portions 318a and 343a in close contact with each other. Further, the first convex portion 316 of the inner cover 31 fits into the slit hole 344 of the front cover 34 with the tapered portions 344a and 316a in close contact with each other. Thereby, the passage PA (FIG. 7A) that penetrates the cover part 30 back and forth is blocked, and communication between the rear space SP1 of the plate part 311 and the front space SP2 of the plate part 341 is blocked. In this case, as shown in FIG. 8B, the claw portion 312a of the engaging claw 312 is located inside the through hole 347 without protruding from the front surface of the surface cover 34.

The operation of the medicine unit 10 according to this embodiment will be explained. As shown in FIG. 5, the drug unit 10 includes a base portion 20 and a cover portion 30 that are each integrally provided (for example, each cannot be disassembled), and the cover portion 30 is removably provided on the base portion 20. Then, the cover section 30 is attached to the base section 20 with the sheet material 11 impregnated with an aromatic agent (for example, an aroma sheet) accommodated in the holder 22 of the base section 20, and the drug unit 10 is assembled.

When attaching the assembled drug unit 10 to the vehicle 1, the rear adhesive surface 212 of the adhesive tape 21 affixed to the back side of the base portion 20 is exposed, and the drug unit 10 is attached to the front end surface 4a of the rear door 4 as shown in FIG. . Further, as shown in FIG. 3, a cushioning material 15 is attached to the rear end surface 5a of the center pillar 5, which faces the front end surface of the drug unit 10. The cushioning material 15 is a plate-like member made of an elastic material such as a resin material or a rubber material, and is formed into a generally rectangular shape as a whole corresponding to the external shape of the drug unit 10. An adhesive surface is formed on the front surface of the cushion material 15 by pasting double-sided tape, for example, and the cushion material 15 is adhered to the rear end surface 5a of the center pillar 5 via the adhesive surface.

9A and 9B are main part sectional views showing an example of the operation of the medicine unit 10, and are views in which the base portion 20 and the sheet material 11 are added to FIGS. 7A and 7B. Therefore, the sheet material 11 is accommodated in the rear space SP1 of the inner cover 31, that is, the space between the inner cover 31 and the holder 22. Note that FIG. 9A corresponds to the operation when the rear door 4 is opened, and FIG. 9B corresponds to the operation when the rear door 4 is closed. In FIG. 9B, illustration of the spring 33 is omitted for convenience.

As shown in FIG. 9A, when the rear door 4 is opened, the front cover 34 is urged forward by the spring 33, and a space SP0 is created between the inner cover 31 (plate part 311) and the front cover 34 (plate part 341). It is formed. For this reason, a passage PA (see FIG. 7A) is released.

As a result, air flows through the passage PA as shown by the arrow in FIG. 9A, and the scent of the aromatic agent in the sheet material 11 can be efficiently diffused toward the front space SP2, which is the opening of the rear door 4. Therefore, the occupant feels the fragrance when getting on and off the vehicle 1, and the comfort of the occupant is improved. In particular, since an air flow is generated around the rear door 4 when the rear door 4 is opened, it is easy to generate an air flow passing through the sheet material 11, and the scent diffusion effect is high.

In this embodiment, the slit holes 318 of the inner cover 31 and the slit holes 344 of the front cover 34 are formed to be vertically shifted from each other. Therefore, when the rear door 4 is opened, dust, raindrops, etc. can be prevented from entering from the front space SP2 into the rear space SP1, and deterioration of the medicine unit 10 can be suppressed. The surface cover 34 has not only a slit hole 344 formed on the front surface but also slit holes 342a formed on the left and right sides, so that the fragrance can be diffused over a wide area around the drug unit 10 when the rear door 4 is opened. Can be done. The slit holes 344 and 342a are formed with their vertical positions shifted from each other, so that the slit holes 344 and 342a are formed continuously over the entire length of the surface cover 43 in the vertical direction. can be diffused well.

As shown in FIG. 9B, when the rear door 4 is closed, the front cover 34 comes into contact with the sealing material 32, and the convex part 343 of the front cover 34 fits into the slit hole 318 of the inner cover 31, and the first convex part of the inner cover 31 316 are fitted into the slit holes 344 of the front cover 34, respectively. As a result, the passage PA (FIG. 7A) that communicates the rear space SP1 of the inner cover 31 with the front space of the front cover 34 is blocked, and the sheet material 11 is placed in the sealed rear space SP1. Therefore, volatilization of the aromatic agent can be suppressed, and the aromatic effect can be continuously exerted when the rear door 4 is opened. Furthermore, since the medicine unit 10 is sealed when the rear door 4 is closed, it is possible to prevent foreign substances such as dust and water droplets from entering the medicine unit 10, and a stable fragrance effect can be obtained when the rear door 4 is opened. It will be done.

When the sheet material 11 dries due to the diffusion of the scent from the drug unit 10 and the aroma effect is reduced, the occupant removes the cover portion 30 with the base portion 20 of the drug unit 10 adhered to the rear door 4 and removes the drug. Disassemble unit 10. Thereby, the sheet material 11 can be replaced, and the drug unit 10 can be used continuously. The occupant can easily remove the cover part 30 by pushing the side wall 314 of the inner cover 31 outward in the left-right direction, thereby making it easy to attach and detach the sheet material 11 and replace it.

According to this embodiment, the following effects can be achieved.
(1) The drug unit 10 is connected to a pair of opposing surfaces on the vehicle body frame 2 side and the rear door 4 side that face each other when the rear door 4 provided on the vehicle body frame 2 is closed, that is, the rear end surface 5a of the center pillar 5 and the front end of the rear door 4. It is provided in the gap CL between the surface 4a (FIG. 3). The drug unit 10 includes a case that accommodates a sheet material 11 impregnated with a volatile drug (fragrance), that is, a base portion 20 and a cover portion 30 (FIGS. 4 and 5). The drug unit 10 (base part 20, cover part 30) has a generally flat shape so that it is disposed in the gap CL between the rear end surface 5a of the center pillar 5 and the front end surface 4a of the rear door 4 when the rear door 4 is closed. (Figure 4). The base portion 20 has a rear adhesive surface 212 that is attached to the front end surface 4a of the rear door 4 (FIG. 6).

As a result, the drug unit 10 having a simple configuration can effectively generate a fragrance near the door opening when the rear door 4 is opened. That is, the drug unit 10 can be easily retrofitted to the vehicle 1 without configuring the vehicle 1 to separately provide a space for installing the drug unit 10. Further, when the rear door 4 is closed, the sheet material 11 can be kept in a sealed state, thereby suppressing volatilization of the aromatic agent and allowing the aromatic effect to be exerted over a long period of time.

(2) The drug unit 10 further includes a cushion material 15 attached to the rear end surface 5a of the center pillar 5 so as to press the cover part 30 when the rear door 4 is closed (FIG. 3). Thereby, regardless of variations in the gap CL between the rear door 4 and the center pillar 5, a predetermined pressing force can be applied to the medicine unit 10 via the cushioning material 15 when the rear door 4 is closed, and the medicine unit 10 can be kept well sealed. Further, since the cushioning material 15 is a resilient member, it is possible to suppress the impact when the medicine unit 10 and the cushioning material 15 come into contact with each other when the rear door 4 is closed.

(3) The drug unit 10 includes a sheet material 11 impregnated with an aromatic agent and housed in a case (between the base part 20 and the cover part 30) (FIG. 5). Thereby, by replacing the sheet material 11 when the aromatic effect is reduced over time, the aromatic effect can be exerted again. That is, the aromatic effect can be maintained with an inexpensive configuration that requires simply replacing the sheet material 11. Note that instead of replacing the sheet material 11, the aromatic effect can also be maintained by impregnating the sheet material 11 with an additional aromatic agent. Furthermore, since the sheet material 11 has a simple shape, it is easy to handle, and the work of replacing the sheet material 11 can be easily performed. Furthermore, by using the sheet material 11, the drug unit 10 can be formed thin as a whole, and the drug unit 10 can be easily placed in the limited gap CL between the rear door 4 and the center pillar 5.

(4) The cover part 30 has a passage PA that communicates the rear space SP1 of the cover part 30 in which the medicine (fragrance) is accommodated with the front space SP2 of the cover part 30 (FIG. 7A). The front cover 34 of the cover part 30 is provided so as to be movable in the front and rear directions with respect to the inner cover 31. In the medicine unit 10, when the front cover 34 is pushed rearward by the pressing force from the cushioning material 15, the passage PA is blocked, while the pressing force from the cushioning material 15 is removed and the front cover 34 is moved by the spring 33. It is configured to open the passage PA when pushed forward (FIGS. 7A and 7B). That is, as the front cover 34 moves in the front-back direction, the slit holes 318 and 344 of the cover part 30 are closed or opened, and the passage PA is closed or opened. As a result, the fragrance component can be kept in the sheet material 11 for a long period of time, and the aromatic effect can be sustained.

(5) A fragrance is used as the medicine inside the medicine unit 10. This allows the occupant to feel the fragrance when getting on and off the vehicle 1, improving the comfort of the occupant.

(6) The medicine inside the medicine unit 10 can also be used as a repellent. Thereby, insects and the like can be prevented from entering the vehicle through the rear door 4.

(7) The vehicle 1 according to the present embodiment includes a drug unit 10, a vehicle body frame 2 in which an opening for a rear door 4 is formed, and a rear door 4 provided in the vehicle body frame 2 to open and close the opening. Prepare (Figures 1 to 3). The rear door 4 has a front end surface 4a as an attachment surface to which the drug unit 10 is attached (FIG. 3). By attaching the drug unit 10 to the rear door 4 in this manner, the odor can be efficiently diffused along the passenger's flow line.

This embodiment can be modified into various forms. Some modified examples will be described below. In the above embodiment, the drug unit 10 is attached to the front end surface 4a of the sliding rear door 4, but it may be attached to another position of the rear door 4 or other than the rear door 4, and the attachment position of the drug unit 10 is It is not limited to those mentioned above. FIG. 10 is a perspective view showing an example in which the drug unit 10 is attached to the front door 3 on the driver's seat side. In the example of FIG. 10, the medicine unit 10 is attached to the upper end surface of the front door 3 in a substantially horizontal position so that the longitudinal direction of the medicine unit 10 is the front-rear direction. Although not shown, the rear door may be configured as a hinge-type rear door that can rotate about the hinge part, and the drug unit 10 may be arranged between the rear end of the rear door and the C-pillar. .

The drug unit 10 may be attached to the vehicle body side (vehicle frame 2 side) instead of the door side. For example, the medicine unit 10 may be attached to the rear end surface 5a of the center pillar 5, and the cushion material 15 may be attached to the front end surface 4a of the rear door 4. That is, of a pair of opposing surfaces (front end surface 4a, rear end surface 5a) facing each other, the first opposing surface, which is the mounting surface to which the drug unit 10 is attached, and the second opposing surface, to which the cushioning material 15 is attached, are connected to the door. It may be either on the side or on the vehicle body side. If the drug unit 10 is attached to the vehicle body side, the scent can be efficiently diffused to the occupants inside the vehicle. On the other hand, if the drug unit is attached to the door side, the scent can be diffused in a location away from the vehicle body.

In the above embodiment, the single drug unit 10 is attached to the rear door 4 via the rear adhesive surface 212 (attachment surface). That is, although a single drug unit 10 is attached to a single door, a plurality of drug units 10 may be attached to a single door at least on the door side or the vehicle body side. FIG. 11 is a perspective view of the vehicle 1 showing an example thereof. In FIG. 11, a plurality of drug units 10 are attached to a back door 6 that is provided so as to be rotatable in the vertical direction using its upper end as a fulcrum. That is, the drug units 10 are attached to the lower end of the back door 6 and to the outside (right side, left side, and lower side) of the opening of the vehicle body frame 2 facing the peripheral edge of the back door 6. This allows the scent to be diffused over a wide area. If some of the scent components are used up, other scent components can maintain the scent effect.

Instead of attaching multiple drug units to a single door, a single drug unit may be attached to multiple doors. FIG. 12 is a front view of a part of the center pillar 5 schematically showing an example thereof, and more specifically, a front view of the vicinity of the center portion of the center pillar 5 in the vertical direction. In FIG. 12, the center pillar 5 The medicine unit 10A is attached to the. Therefore, the medicine unit 10A is configured to have a wide width, and when the front and rear doors are closed, the front side of the medicine unit 10A is pressed by the front door, and the rear side of the medicine unit 10A is pressed by the rear door. Thereby, the number of drug units 10A can be saved.

In the above embodiment, the medicine unit 10 is pressed through the cushion material 15 when the door is closed, but the configuration of the pressing member is not limited to that described above. In the above embodiment, the sheet material 11 is housed between the base part 20 and the cover part 30, but if a volatile drug is stored in the case, a material other than the sheet material may be used. good. In the above embodiment, the case is configured by the base portion 20 and the cover portion 30, but the configuration of the case is not limited to this. In the embodiment described above, the first convex portion 316 and the convex portion 343 are fitted into the slit holes 318 and 344 to close the passage PA that communicates the sheet material 11 and the front space SP2 (external space). However, the configuration of the shutter section is not limited to this. In the above embodiment, a fragrance is used as a medicine, but a repellent may also be used as a medicine. The repellent may be odorless. Other volatile agents may be used instead of fragrances and repellents. For example, various volatile and odorless chemicals may be used.

When using an aromatic agent as a medicine, if the medicine unit 10 is installed at a position as shown in FIG. 2, for example, the medicine unit 10 can be positioned near the upper half of the face of a person who gets in and out of the vehicle through the rear door 4. This allows the fragrance to be delivered efficiently. On the other hand, when using a repellent as a medicine, if the medicine unit 10 is installed at the periphery of the back door 6 as shown in FIG. can be located. Thereby, the effect of the repellent can be extended over a wide range. In addition, when a plurality of medicine units 10 are installed in a single door as shown in FIG. 11, a medicine unit having an aromatic agent and a medicine unit having a repellent may be respectively installed. Thereby, the effect of the fragrance and the effect of the repellent can be obtained at the same time.

In the above embodiment, the drug unit 10 is provided between the rear door 4 and the center pillar 5, which is a part of the vehicle body frame 2. A drug unit may be provided between the door (end face, etc.) and the door. That is, the drug unit may be provided between the vehicle body other than the vehicle body frame 2 and the door.

The above description is merely an example, and the present invention is not limited to the above-described embodiments and modifications as long as the characteristics of the present invention are not impaired. It is also possible to arbitrarily combine the above embodiment and one or more of the modifications, and it is also possible to combine the modifications.

1 vehicle, 2 body frame, 4 rear door, 4a front end surface, 5 center pillar, 5a rear end surface, 10, 10A drug unit, 11 sheet material, 15 cushion material, 20 base portion, 30 cover portion, 212 rear adhesive surface, PA aisle, SP2 front space

Claims (8)

A drug unit provided between a pair of opposing surfaces on the vehicle body side and the door side that face each other when a door provided on the vehicle body is closed,
a case having a generally flat shape so as to be disposed in the gap between the pair of opposing surfaces when the door is closed, and containing a volatile drug;
The pair of opposing surfaces are a first opposing surface on one of the vehicle body side and the door side, and a second opposing surface on the other,
The case is
a mounting surface that is attached to the first opposing surface ; a passage that communicates the medicine with the external space of the case; and a pressing force from the second opposing surface that blocks the passage; a shutter portion configured to open the passage when a pressing force from the medicine unit is removed . The drug unit according to claim 1,
The medicine unit further comprising a pressing member attached to the second opposing surface so as to press the case when the door is closed. The drug unit according to claim 1 or 2,
A drug unit further comprising a sheet material impregnated with the drug and housed in the case. The drug unit according to any one of claims 1 to 3,
A drug unit, wherein the drug is an aromatic agent. The drug unit according to any one of claims 1 to 3,
A drug unit, wherein the drug is a repellent. A drug unit according to any one of claims 1 to 5,
A vehicle body having an opening formed therein;
a door provided on the vehicle body to open and close the opening;
The vehicle is characterized in that the vehicle main body or the door has an attachment surface to which the drug unit is attached. The vehicle according to claim 6,
A vehicle characterized in that the vehicle main body or the door has a plurality of attachment surfaces so that a plurality of drug units can be attached to a single door. The vehicle according to claim 6 or 7,
The door includes a first door and a second door disposed adjacent to the first door,
The vehicle body is characterized in that the vehicle body has the mounting surface such that the drug unit faces the first door and the second door, respectively, when the first door and the second door are closed. .

Images